How Fast Are Phase III Nephrology CTIS Reviews and What Signals Delay?
Across 53 Phase III nephrology trials, the median CTIS/EU end-to-end authorization time was 90 days (SD 44.5). Country-specific CTIS Part II processing had a similar median of 96 days but far greater dispersion (SD 288.2 across 221 country decisions). Placebo control, larger enrolment and selected disease/modality groups tracked with longer timelines, while open-label design and CRO-supported submissions tracked with shorter authorization.
What exactly is being timed?
The analysis separates the coordinated CTIS/EU application outcome from the Member State–specific Part II process, avoiding an invalid country-level end-to-end comparison.
How long does end-to-end CTIS/EU authorization take?
The typical Phase III nephrology application reached authorization in 90 days. The middle 50% ranged from 35 to 109 days, and 48 of 53 trials (90.6%) were authorized within 120 days.
The 90-day median splits the cohort almost exactly: 26 trials were faster than 90 days and 27 took 90 days or longer. Only 5 of 53 (9.4%) reached 120 days or more, indicating that the long tail was concentrated in a small subset.
How long does country-specific CTIS Part II take?
Across 221 Member State decisions, the Part II median was 96 days. Among countries with at least three observations, the median ranged from 21 days in the Netherlands to 602.5 days in Lithuania.
| Country | n | Median | SD |
|---|---|---|---|
| Netherlands | 10 | 21 | 286.8 |
| Norway | 4 | 24 | 394.7 |
| Denmark | 8 | 31 | 346.9 |
| Ireland | 1 | 35 | — |
| Slovakia | 3 | 35 | 455.1 |
| Austria | 6 | 48.5 | 391.6 |
| Czechia | 12 | 61 | 282.4 |
| Hungary | 7 | 64 | 327.1 |
| Slovenia | 1 | 74 | — |
| Greece | 7 | 84 | 276.4 |
| Belgium | 12 | 93 | 246.0 |
| Spain | 26 | 111.5 | 264.8 |
| Country | n | Median | SD |
|---|---|---|---|
| Germany | 22 | 156 | 305.3 |
| Bulgaria | 5 | 172 | 326.9 |
| Portugal | 8 | 180 | 286.2 |
| Sweden | 8 | 181 | 348.2 |
| France | 27 | 214 | 271.1 |
| Poland | 17 | 229 | 296.2 |
| Romania | 4 | 237 | 277.3 |
| Italy | 23 | 256 | 267.0 |
| Finland | 2 | 398 | 540.2 |
| Croatia | 2 | 400.5 | 265.2 |
| Lithuania | 4 | 602.5 | 330.2 |
| Estonia | 2 | 606 | 33.9 |
Country medians were materially more dispersed than trial-level authorization. The Netherlands (21 days, n=10), Norway (24, n=4) and Denmark (31, n=8) formed the fastest multi-observation group; Lithuania (602.5, n=4) was the slowest among countries with at least three records.
What share of Part II decisions falls within practical planning windows?
Part II was split around the three-month mark: 106 of 221 country decisions (48.0%) were completed within 90 days, while 101 (45.7%) reached 180 days or longer.
Which submission months were associated with faster or slower timelines?
Month-of-year patterns were visible without using submission year. For end-to-end authorization, February had the fastest median among months with at least four trials (40 days, n=7), while January and July both reached 108 days.
Part II timing showed a different seasonal pattern: April and May submissions had medians of 27 and 32 days, whereas February and July reached 617 and 596 days. Month is therefore a planning signal, but its direction differs between the coordinated application and country-specific Part II.
Which factors tracked with shorter-than-median authorization?
The strongest unadjusted signals for completing authorization in under 90 days were open-label design, CRO involvement and characteristics that may proxy established operational infrastructure.
Median 37 days (n=21) versus 107 days for other designs (n=32).
Median 37 days (n=21) versus 105 days without a recorded CRO (n=32).
Median 37 days (n=9) versus 97 days in non-orphan trials (n=44).
Median 46 days (n=14) versus 105 days in adult-only trials (n=39).
These are exploratory associations rather than causal effects. Open-label design had the clearest median difference (Mann–Whitney p=0.006); CRO presence also tracked with shorter timelines (p=0.036). Orphan and paediatric signals were directionally strong but less precise because the groups were smaller.
Which factors signaled two- or three-month delay?
Overall, 30 of 53 trials (56.6%) took at least 60 days and 27 (50.9%) took at least 90 days. Placebo control and larger planned enrolment were the clearest design-scale delay signals.
Median versus 55 days without placebo; n=24 versus n=29.
Median versus 55 days at or below the cohort median; n=26 versus n=27.
Median versus 68 days for small-molecule trials; n=15 versus n=29.
Highest disease-group median among groups with at least three trials; n=10.
Placebo-controlled trials showed a 53-day median increase and a higher ≥90-day rate than non-placebo designs (66.7% vs 37.9%; distribution p=0.012). The sample-size, modality and disease findings are useful planning signals but overlap with other design and sponsor characteristics.
How did disease and modality shape the timeline?
Disease and intervention type separated the cohort into operationally distinct profiles. Immune/glomerular and CKD/proteinuria programs had the longest disease-group medians, while antibody/biologic trials had the longest modality median.
Do more countries or sites automatically create delay?
Not at the trial-level end-to-end stage. The number of participating countries had a weak inverse correlation with authorization time (Spearman ρ=−0.17), and total sites had almost no correlation (ρ=+0.06). Country-level Part II behaved differently.
Geographic breadth did not materially explain the coordinated CTIS/EU timeline, but local execution scale did track with Part II: the median rose from 41.5 days for one-site country entries to 320 days for entries with six or more sites.
What did the full-dataset signal screen show?
Across design, recruitment, geography, sponsor, drug, eligibility and endpoint variables, only a subset showed meaningful monotonic association with end-to-end timing.
Planning implications for EU Phase III nephrology submissions
A practical base case is 90 days for end-to-end CTIS/EU authorization, but country Part II planning should be country- and site-specific rather than anchored to one European average.